Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
5.83
-0.12 (-2.02%)
At close: Jan 30, 2026, 4:00 PM EST
5.94
+0.11 (1.89%)
After-hours: Jan 30, 2026, 7:30 PM EST
Immix Biopharma Employees
As of December 31, 2024, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,122,040
Market Cap
307.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2023 | 17 | 6 | 54.55% | 14 | 3 |
| Dec 31, 2022 | 11 | 9 | 450.00% | 9 | 2 |
| Dec 31, 2021 | 2 | - | - | 2 | 0 |
| Sep 30, 2021 | 2 | - | - | 2 | 0 |
| Jun 30, 2021 | 2 | - | - | 2 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 172 |
| X4 Pharmaceuticals | 143 |
| Adlai Nortye | 123 |
| Foghorn Therapeutics | 112 |
| Larimar Therapeutics | 65 |
| Atea Pharmaceuticals | 56 |
| Immuneering | 54 |
| Cybin | 50 |
IMMX News
- 3 days ago - Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 - GlobeNewsWire
- 7 weeks ago - Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition - Seeking Alpha
- 7 weeks ago - Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 7 weeks ago - Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 7 weeks ago - At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - GlobeNewsWire
- 2 months ago - Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch - GlobeNewsWire
- 3 months ago - Immix Biopharma: I Am Surprised To Reaffirm A 'Buy' - Seeking Alpha
- 3 months ago - Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - GlobeNewsWire